No Data
US Stock MarketDetailed Quotes
ALT Altimmune
Watchlist
2.520
0.0000.00% Close 09/27 16:00 ET
2.5200.0000.00%
Post 17:45 ET
2.590High2.510Low604.26KVolume
2.530Open2.520Pre Close1.54MTurnover1.22%Turnover RatioLossP/E (TTM)132.77MMarket Cap17.17052wk HighLossP/E (Static)52.69MShares2.34052wk Low0.79P/B124.68MFloat Cap978.000Historical High--Dividend TTM49.47MShs Float-1731.000Historical Low--Div YieldTTM3.18%Amplitude2.540Avg Price1Lot Size
Full Hours
- 5D
- 1D
- 1W
- 1M
- 1Q
- 1Y
About Altimmune Company
Altimmune, Inc. is a clinical stage biopharmaceutical company, which focuses on the development of novel peptide-based therapeutics for the treatment of obesity and liver diseases. The company's lead product candidate, pemvidutide, is a GLP-1/glucagon dual receptor agonist that is being developed for the treatment of obesity and NASH. In addition, Altimmune is developing HepTcell, an immunotherapeutic designed to achieve a functional cure for chronic hepatitis B. The company was founded in 1997 and is headquartered in Gaithersburg, MD.
Revenue Breakdown
Business
Unit:USD
12/31/2022
Stock NameRevenueRatio
Single Segment-68K100.00%
News
Altimmune Announces Oral Presentation of Pemvidutide Clinical Data at 59th Annual Meeting of the European Association for the Study of Diabetes
GAITHERSBURG, Md., Sept. 26, 2023 (GLOBE NEWSWIRE) -- Altimmune, Inc. (NASDAQ:ALT), a clinical-stage biopharmaceutical company, today announced that Dr. Louis J. Aronne, Founder and Director of the Center for Weight
JMP Securities Remains a Buy on Altimmune (ALT)
Catalyst Watch: Microsoft, Amazon, Oracle, and Intel to Hold High-Profile Events
Welcome to Seeking Alpha's Catalyst Watch - a breakdown of some of next week's actionable events that stand out. Check out Saturday morning's regular Stocks to Watch article for a full list of events planned for the week or the Seeking Alpha earnings calendar for companies due to report.
Paper Trade
Start
Symbol
Direction
Buy
Sell
Types
LMT Order
Price
QTY
Amount
--